127 related articles for article (PubMed ID: 10086702)
1. 18F alpha-methyl tyrosine PET studies in patients with brain tumors.
Inoue T; Shibasaki T; Oriuchi N; Aoyagi K; Tomiyoshi K; Amano S; Mikuni M; Ida I; Aoki J; Endo K
J Nucl Med; 1999 Mar; 40(3):399-405. PubMed ID: 10086702
[TBL] [Abstract][Full Text] [Related]
2. Biodistribution studies on L-3-[fluorine-18]fluoro-alpha-methyl tyrosine: a potential tumor-detecting agent.
Inoue T; Tomiyoshi K; Higuichi T; Ahmed K; Sarwar M; Aoyagi K; Amano S; Alyafei S; Zhang H; Endo K
J Nucl Med; 1998 Apr; 39(4):663-7. PubMed ID: 9544678
[TBL] [Abstract][Full Text] [Related]
3. Detection of malignant tumors: whole-body PET with fluorine 18 alpha-methyl tyrosine versus FDG--preliminary study.
Inoue T; Koyama K; Oriuchi N; Alyafei S; Yuan Z; Suzuki H; Takeuchi K; Tomaru Y; Tomiyoshi K; Aoki J; Endo K
Radiology; 2001 Jul; 220(1):54-62. PubMed ID: 11425972
[TBL] [Abstract][Full Text] [Related]
4. Assessment of therapy response in lung cancer with ¹⁸F-α-methyl tyrosine PET.
Kaira K; Oriuchi N; Yanagitani N; Sunaga N; Ishizuka T; Mori M; Endo K
AJR Am J Roentgenol; 2010 Nov; 195(5):1204-11. PubMed ID: 20966329
[TBL] [Abstract][Full Text] [Related]
5. PET imaging of musculoskeletal tumours with fluorine-18 alpha-methyltyrosine: comparison with fluorine-18 fluorodeoxyglucose PET.
Watanabe H; Inoue T; Shinozaki T; Yanagawa T; Ahmed AR; Tomiyoshi K; Oriuchi N; Tokunaga M; Aoki J; Endo K; Takagishi K
Eur J Nucl Med; 2000 Oct; 27(10):1509-17. PubMed ID: 11083540
[TBL] [Abstract][Full Text] [Related]
6. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter.
Spence AM; Muzi M; Mankoff DA; O'Sullivan SF; Link JM; Lewellen TK; Lewellen B; Pham P; Minoshima S; Swanson K; Krohn KA
J Nucl Med; 2004 Oct; 45(10):1653-9. PubMed ID: 15471829
[TBL] [Abstract][Full Text] [Related]
7. Diagnosis of maxillofacial tumor with L-3-[18f]-fluoro-alpha-methyltyrosine (FMT) PET: a comparative study with FDG-PET.
Miyakubo M; Oriuchi N; Tsushima Y; Higuchi T; Koyama K; Arai K; Paudyal B; Iida Y; Hanaoka H; Ishikita T; Nakasone Y; Negishi A; Mogi K; Endo K
Ann Nucl Med; 2007 Feb; 21(2):129-35. PubMed ID: 17424980
[TBL] [Abstract][Full Text] [Related]
8. Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG.
Cook GJ; Houston S; Barrington SF; Fogelman I
J Nucl Med; 1998 Jan; 39(1):99-103. PubMed ID: 9443745
[TBL] [Abstract][Full Text] [Related]
9. Diagnostic usefulness of fluorine-18-alpha-methyltyrosine positron emission tomography in combination with 18F-fluorodeoxyglucose in sarcoidosis patients.
Kaira K; Oriuchi N; Otani Y; Yanagitani N; Sunaga N; Hisada T; Ishizuka T; Endo K; Mori M
Chest; 2007 Apr; 131(4):1019-27. PubMed ID: 17426205
[TBL] [Abstract][Full Text] [Related]
10. Grading of brain glioma with 1-11C-acetate PET: comparison with 18F-FDG PET.
Tsuchida T; Takeuchi H; Okazawa H; Tsujikawa T; Fujibayashi Y
Nucl Med Biol; 2008 Feb; 35(2):171-6. PubMed ID: 18312826
[TBL] [Abstract][Full Text] [Related]
11. Fluorine-18-fluorodeoxyglucose PET versus thallium-201 scintigraphy evaluation of thyroid tumors.
Uematsu H; Sadato N; Ohtsubo T; Tsuchida T; Nakamura S; Sugimoto K; Waki A; Takahashi N; Yonekura Y; Tsuda G; Saito H; Hayashi N; Yamamoto K; Ishii Y
J Nucl Med; 1998 Mar; 39(3):453-9. PubMed ID: 9529291
[TBL] [Abstract][Full Text] [Related]
12. Gliomatosis cerebri evaluated by 18Falpha-methyl tyrosine positron-emission tomography.
Sato N; Inoue T; Tomiyoshi K; Aoki J; Oriuchi N; Takahashi A; Otani T; Kurihara H; Sasaki T; Endo K
Neuroradiology; 2003 Oct; 45(10):700-7. PubMed ID: 13680026
[TBL] [Abstract][Full Text] [Related]
13. In vivo comparison of PET and SPECT radiopharmaceuticals in detecting breast cancer.
Amano S; Inoue T; Tomiyoshi K; Ando T; Endo K
J Nucl Med; 1998 Aug; 39(8):1424-7. PubMed ID: 9708521
[TBL] [Abstract][Full Text] [Related]
14. Can the standardized uptake value characterize primary brain tumors on FDG-PET?
Hustinx R; Smith RJ; Benard F; Bhatnagar A; Alavi A
Eur J Nucl Med; 1999 Nov; 26(11):1501-9. PubMed ID: 10552096
[TBL] [Abstract][Full Text] [Related]
15. Voxel-based analysis of dual-time-point 18F-FDG PET images for brain tumor identification and delineation.
Prieto E; Martí-Climent JM; Domínguez-Prado I; Garrastachu P; Díez-Valle R; Tejada S; Aristu JJ; Peñuelas I; Arbizu J
J Nucl Med; 2011 Jun; 52(6):865-72. PubMed ID: 21571807
[TBL] [Abstract][Full Text] [Related]
16. Schwannoma of the extremities: the role of PET in preoperative planning.
Ahmed AR; Watanabe H; Aoki J; Shinozaki T; Takagishi K
Eur J Nucl Med; 2001 Oct; 28(10):1541-51. PubMed ID: 11685498
[TBL] [Abstract][Full Text] [Related]
17. Fluorine-18-FDG PET and iodine-123-IMT SPECT in the evaluation of brain tumors.
Weber W; Bartenstein P; Gross MW; Kinzel D; Daschner H; Feldmann HJ; Reidel G; Ziegler SI; Lumenta C; Molls M; Schwaiger M
J Nucl Med; 1997 May; 38(5):802-8. PubMed ID: 9170450
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of FDG PET in patients with cervical cancer.
Sugawara Y; Eisbruch A; Kosuda S; Recker BE; Kison PV; Wahl RL
J Nucl Med; 1999 Jul; 40(7):1125-31. PubMed ID: 10405131
[TBL] [Abstract][Full Text] [Related]
19. Dexamethasone treatment and plasma glucose levels: relevance for fluorine-18-fluorodeoxyglucose uptake measurements in gliomas.
Roelcke U; Blasberg RG; von Ammon K; Hofer S; Vontobel P; Maguire RP; Radü EW; Herrmann R; Leenders KL
J Nucl Med; 1998 May; 39(5):879-84. PubMed ID: 9591593
[TBL] [Abstract][Full Text] [Related]
20. Metabolic characterization of childhood brain tumors: comparison of 18F-fluorodeoxyglucose and 11C-methionine positron emission tomography.
Utriainen M; Metsähonkala L; Salmi TT; Utriainen T; Kalimo H; Pihko H; Mäkipernaa A; Harila-Saari A; Jyrkkiö S; Laine J; Någren K; Minn H
Cancer; 2002 Sep; 95(6):1376-86. PubMed ID: 12216107
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
